Pareek A.,Clinical Research Laboratories |
Chandurkar N.,Clinical Research Laboratories |
Gupta A.,Mahatma Gandhi Medical College and Hospital |
Sirsikar A.,JA Group of Hospitals |
And 4 more authors.
Journal of Pain | Year: 2011
The efficacy and safety of aceclofenac control release (CR) tablets was compared with conventional aceclofenac tablets in patients with knee osteoarthritis (OA). This was a double-blind, double-dummy, randomized, parallel group multicentric study conducted at 6 centers. Two hundred and eighty five patients were randomized to either aceclofenac-CR (n = 143) once daily or conventional aceclofenac tablet (n = 142) twice daily and were followed for 6 weeks. The efficacy parameters were pain intensity score on visual analogue scale, Western Ontario and McMaster (WOMAC) score, patients and investigator's overall study drug assessment and total consumption of acetaminophen and ranitidine tablets. Both treatments showed significant improvement in their efficacy parameters from baseline at the end of therapy. Aceclofenac-CR was comparable to conventional aceclofenac with respect to change in pain intensity and WOMAC score (P > .05) There was no statistically significant difference between the treatment groups in patient's and investigator's overall study drug assessment at the end of therapy (P > .05). Aceclofenac-CR treated patients took fewer acetaminophen and ranitidine tablets during the treatment period as compared to conventional aceclofenac treated patients. Both the study medications were well tolerated with no incidence of serious adverse event (SAE). In conclusion, the new aceclofenac-CR formulation was found to be effective and safe while offering practical advantage of once daily administration. Perspective: This article represents the advantages of control release aceclofenac over the conventional aceclofenac tablets. Aceclofenac-CR was found to be similar in terms of efficacy as conventional aceclofenac in knee OA patients with fewer adverse events. © 2011 by the American Pain Society.
Natu N.,Sri Aurobindo Institute of Medical science |
Khandelwal S.,Sri Aurobindo Institute of Medical science |
Kumar R.,Sri Aurobindo Institute of Medical science |
Dave A.,Mahatma Gandhi Memorial Medical College
Hemoglobin | Year: 2014
Pregnancy in sickle cell disease is associated with increased risk of maternal and fetal morbidity and mortality. Sickle cell disease is very common in tribal populations. The objective of this study was to review the maternal and perinatal outcome in patients with sickle cell disease of tribal populations. This is a retrospective study. The data extracted from the patients' case files included age, gravidity, family history, complications during pregnancy or at time of delivery or postpartum period, mode of delivery, and fetal outcome. There were 25 deliveries to women with sickle cell disease and 54 with sickle cell trait. Preeclampsia and disseminated intravascular coagulation were common problems associated with sickle cell disease as compared to the sickle cell trait and normal groups. No maternal mortality occurred during the period under study. However, a total of five intrauterine fetal deaths and one early neonatal death did occur. The present study confirms the previous reports, the increased risk of fetal death in women with sickle cell disease, however, in contrast to previous studies, no maternal mortality was found. © 2014 Informa Healthcare USA, Inc. All rights reserved: reproduction in whole or part not permitted.
Sutter R.W.,World Health Organization |
John T.J.,India Expert Advisory Group on Polio Eradication |
Jain H.,Mahatma Gandhi Memorial Medical College |
Agarkhedkar S.,Dr D Y Patil Medical College |
And 10 more authors.
The Lancet | Year: 2010
Poliovirus types 1 and 3 co-circulate in poliomyelitis-endemic countries. We aimed to assess the immunogenicity of a novel bivalent types 1 and 3 oral poliovirus vaccine (bOPV). We did a randomised, double-blind, controlled trial to assess the superiority of monovalent type 2 OPV (mOPV2), mOPV3, or bOPV over trivalent OPV (tOPV), and the non-inferiority of bivalent vaccine compared with mOPV1 and mOPV3. The study was done at three centres in India between Aug 6, 2008, and Dec 26, 2008. Random allocation was done by permuted blocks of ten. The primary outcome was seroconversion after one monovalent or bivalent vaccine dose compared with a dose of trivalent vaccine at birth. The secondary endpoints were seroconversion after two vaccine doses compared with after two trivalent vaccine doses and cumulative two-dose seroconversion. Parents or guardians and study investigators were masked to treatment allocation. Because of multiple comparisons, we defined p≤0·01 as statistically significant. This trial is registered with Current Controlled Trials, ISRCTN 64725429. 900 newborn babies were randomly assigned to one of five vaccine groups (about 180 patients per group); of these 70 (8) discontinued, leaving 830 (92) for analysis. After the first dose, seroconversion to poliovirus type 1 was 20 for both mOPV1 (33 of 168) and bOPV (32 of 159) compared with 15 for tOPV (25 of 168; p>0·01), to poliovirus type 2 was 21 (35 of 170) for mOPV2 compared with 25 (42 of 168) for tOPV (p>0·01), and to poliovirus type 3 was 12 (20 of 165) for mOPV3 and 7 (11 of 159) for bOPV compared with 4 (7 of 168) for tOPV (mOPV3 vs tOPV p=0·01; bOPV vs tOPV; p>0·01). Cumulative two-dose seroconversion to poliovirus type 1 was 90 (151 of 168) for mOPV1 and 86 (136 of 159) for bOPV compared with 63 (106 of 168) for tOPV (p<0·0001), to poliovirus type 2 was 90 (153 of 170) for mOPV2 compared with 91 (153 of 168) for tOPV (p>0·01), and to poliovirus type 3 was 84 (138 of 165) for mOPV3 and 74 (117 of 159) for bOPV compared with 52 (87 of 168) for tOPV (p<0·0001). The vaccines were well tolerated. 19 serious adverse events occurred, including one death; however, these events were not attributed to the trial interventions. The findings show the superiority of bOPV compared with tOPV, and the non-inferiority of bOPV compared with mOPV1 and mOPV3. GAVI Alliance, World Health Organization, and Panacea Biotec. © 2010 Elsevier Ltd.
Saklani R.,University of Delhi |
Gupta S.K.,University of Delhi |
Mohanty I.R.,Mahatma Gandhi Memorial Medical College |
Kumar B.,Tufts University |
And 2 more authors.
Molecular and Cellular Biochemistry | Year: 2016
Diabetic cardiomyopathy (DCM) is a dreadful complication of diabetes responsible for 80 % mortality in diabetic patients, but unfortunately its pharmacotherapy is still incomplete. Rutin is a naturally occurring flavonoid having a long history of use in nutritional supplements for its action against oxidative stress, inflammation, and hyperglycemia, the key players involved in the progression of DCM, but remains unexplored for its role in DCM. This study was conducted to address this lacuna. It was performed in 4-week-old Streptozotocin-induced (45 mg/kg) diabetic rats for a period of 24 weeks to mimic the cardiotoxic effect of chronic hyperglycemia in diabetic patient’s heart and to investigate the effect of rutin (50 mg/kg/day) in ameliorating these effects. Heart of the diabetic rats showed altered ECG parameters, reduced total antioxidant capacity, increased inflammatory assault, and degenerative changes. Interestingly, rutin treatment significantly ameliorated these changes with decrease in blood glucose level (p > 0.001), % HbA1c (p > 0.001) and reduced expression of TNF-α (p < 0.001), CRP (p < 0.001), and BNP (p < 0.01) compared to diabetic control rats. In addition, rutin provided significant protection against diabetes associated oxidative stress (p < 0.05), prevented degenerative changes in heart, and improved ECG parameters compared to diabetic control rats. The heart-to-body weight ratio was significantly reduced in rutin treatment group compared to diabetic control rats (p < 0.001). In conclusion, this study implicates that oxidative stress and inflammation are the central players involved in the progression of DCM and rutin ameliorates DCM through its antioxidant and anti-inflammatory actions on heart. © 2016 Springer Science+Business Media New York
Nagar R.,Mahatma Gandhi Memorial Medical College |
Sengar S.S.,Mahatma Gandhi Memorial Medical College
Journal of Cutaneous and Aesthetic Surgery | Year: 2016
Iontophoresis is defined as passing of an ionized substance through intact skin by application of direct electric current. Tap water iontophoresis is reliable and effective method for treatment of palmar and plantar hyperhydrosis when practiced with appropriate technique and timing.One of the major setback for using iontophoresis is that the apparatus is expensive and is not readily available.A simple user-made Iontophoresis device have been described here, which could be easily constructed and used at home.